RxDoctor Payments Data

Lawrence Knab

Surgical Oncology · Hershey, PANPI 1467786988

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,083 of the $1,626 with a category attached, or 66.6%. 6 manufacturers reported payments, led by Intuitive Surgical at 53.5% of the total. Reporting peaked in 2020 at $679 and has fallen 63.4% since, to $249 in 2023.

$1,626in general payments, 2019–2025

Across 25 payments — averaging $65.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$870
  • Covidien LP$255
  • Johnson & Johnson$241
  • W. L. Gore & Associates, Inc.$138
  • Coherus Oncology, Inc.$102
  • Cardinal Health 414 LLC$20

What the payments were for

  • Travel & lodging$54333%
  • Food & beverage$1,08367%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,626 in reported general payments places this provider in the 55th percentile of 78 surgical oncology providers in Pennsylvania.

See all surgical oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$60,784
Medicare patients
87
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase16$30,193

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →